Pilot Trial of Cognitive and Behavioral Treatment of Compulsive Hoarding Compared to Wait List Control

NCT ID: NCT00073346

Last Updated: 2020-01-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-09-01

Study Completion Date

2008-07-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study developed and tested a specialized cognitive and behavioral treatment for the symptoms of hoarding disorder, including excessive acquiring, difficulty discarding items, and extensive clutter in the home.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Compulsive hoarding is characterized by excessive acquisition of possessions, difficulty discarding possessions, and excessive clutter. This condition is resistant to standard pharmacological and psychotherapeutic interventions that have proven effective in treating other obsessive compulsive spectrum disorders. This study aimed to determine the effectiveness of a specialized cognitive behavioral therapy (CBT) designed for treating hoarding symptoms.

This study consists of three phases. In Phase 1, pilot data from previous studies were examined to develop an intervention suitable for use in a waitlist trial. In Phase 2, pilot study information were used to develop and test a treatment manual for compulsive hoarding. During this phase, treatment was applied flexibly to allow for variations in treatment duration and choice of techniques. During Phase 3, participants were randomly assigned to 26 weekly sessions of CBT or to a 12-week wait-list control, followed by active treatment for a fixed duration of 26 sessions. Therapist adherence and competence were assessed through audiotaped therapy sessions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obsessive-Compulsive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

active treatment versus wait list control
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cognitive behavior therapy for hoarding disorder

Cognitive behavior therapy included 26 sessions of motivational enhancements; skills training for sorting, organizing and problem solving; direct practice not acquiring new items and discarding possessions to remove clutter and organize possessions; cognitive therapy to evaluate beliefs about possessions; and relapse prevention skills.

Group Type EXPERIMENTAL

Cognitive Behavioral Treatment

Intervention Type BEHAVIORAL

Wait list control

Participants waited to receive treatment for 12 weeks

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cognitive Behavioral Treatment

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Display at least moderately severe hoarding symptoms
* Must live within 45 minutes of Boston, MA or Hartford, CT

Exclusion Criteria

* Ten or more sessions of cognitive behavior therapy for hoarding
* Concurrent psychotherapy or medications
* Suicidal, psychotic, or other psychiatric symptoms requiring hospitalization
* Compulsive buying symptoms that are part of a manic phase of bipolar disorder
* Mental retardation, dementia, brain damage, or other cognitive dysfunction that would interfere with the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Mental Health (NIMH)

NIH

Sponsor Role collaborator

Boston University Charles River Campus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gail Steketee

Role: PRINCIPAL_INVESTIGATOR

Boston University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hartford Hospital, Institute of Living

Hartford, Connecticut, United States

Site Status

BostonUCRC

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.ocfoundation.org

Click here for more information about compulsive hoarding.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R21MH068539

Identifier Type: NIH

Identifier Source: secondary_id

View Link

DATR A2-AIA

Identifier Type: -

Identifier Source: secondary_id

R21MH068539

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

iCBT for Adult Obsessive-Compulsive Disorder
NCT07081438 NOT_YET_RECRUITING NA
Treatment of Hypochondriasis With CBT and/or SSRI
NCT00339079 COMPLETED PHASE1/PHASE2